Pioglitazone/metformin

Drug Profile

Pioglitazone/metformin

Alternative Names: ACTOplus met; ACTOplus met XR; AD 48833MET; Competact; Glubrava; Metact; Metformin/pioglitazone; Metformin/pioglitazone XR

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda; Takeda Pharmaceuticals North America
  • Developer Takeda; Takeda Pharmaceuticals USA
  • Class Antihyperglycaemics; Biguanides; Small molecules; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 30 Apr 2015 Launched for Type-2 diabetes mellitus in Greece and Austria (PO) before April 2015
  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
  • 17 Aug 2012 Generic equivalent available in USA for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top